FDA Orders Singulair Inhaler To Carry Black Box For Behavior, Mood Changes

(March 5, 2020, 2:23 PM EST) -- SILVER SPRING, Md. — The Food and Drug Administration on March 4 ordered a black box warning about serious behavior and mood-related risks for Singulair-brand montelukast, an inhaler first approved 22...
To view the full article, register now.